Inadequate use of antibiotics in the covid-19 era: effectiveness of antibiotic therapy

Background: Since December 2019, the COVID-19 pandemic has changed the concept of medicine. This work aims to analyze the use of antibiotics in patients admitted to the hospital due to SARS-CoV-2 infection. Methods: This work analyzes the use and effectiveness of antibiotics in hospitalized patients...

Descripción completa

Detalles Bibliográficos
Autores: Bendala Estrada, Alejandro David, Calderón Parra, Jorge, Fernández Carracedo, Eduardo, Muiño Míguez, Antonio, Ramos Martínez, Antonio, Muñez Rubio, Elena, Rubio Rivas, Manuel, Agudo, Paloma, Arnalich Fernández, Francisco, Estrada, Vicente, Taboada-Martínez, María Luisa, Crestelo Vieitez, Anxela, Pesqueira Fontán, Paula María, Bustamante, Marta F., Freire, Santiago Jesús, Oriol, Isabel, Artero, Arturo, Olalla, Julián, Areses Manrique, María, Carrasco Sánchez, Francisco, Vento, Vanessa Carolina, García García, Gema María, Cubero Morais, Pablo, Casas Rojo, José, Núñez Cortés, Jesús Millán
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/181343
Acceso en línea:https://hdl.handle.net/2445/181343
Access Level:acceso abierto
Palabra clave:Antibiòtics
COVID-19
Supervivència
Antibiotics
Survival
Descripción
Sumario:Background: Since December 2019, the COVID-19 pandemic has changed the concept of medicine. This work aims to analyze the use of antibiotics in patients admitted to the hospital due to SARS-CoV-2 infection. Methods: This work analyzes the use and effectiveness of antibiotics in hospitalized patients with COVID-19 based on data from the SEMI-COVID-19 registry, an initiative to generate knowledge about this disease using data from electronic medical records. Our primary endpoint was all-cause in-hospital mortality according to antibiotic use. The secondary endpoint was the effect of macrolides on mortality. Results: Of 13,932 patients, antibiotics were used in 12,238. The overall death rate was 20.7% and higher among those taking antibiotics (87.8%). Higher mortality was observed with use of all antibiotics (OR 1.40, 95% CI 1.21-1.62; p < .001) except macrolides, which had a higher survival rate (OR 0.70, 95% CI 0.64-0.76; p < .001). The decision to start antibiotics was influenced by presence of increased inflammatory markers and any kind of infiltrate on an x-ray. Patients receiving antibiotics required respiratory support and were transferred to intensive care units more often. Conclusions: Bacterial co-infection was uncommon among COVID-19 patients, yet use of antibiotics was high. There is insufficient evidence to support widespread use of empiric antibiotics in these patients. Most may not require empiric treatment and if they do, there is promising evidence regarding azithromycin as a potential COVID-19 treatment.

Similares en LA Referencia